GlassScriptPhysician profile
Angela K Ames
NPI 1427608710
$3,965.28
in general payments reported to CMS, 2019-2025
27 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $887 · 2023: $819 · 2024: $1,245 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.57 | 2021-2025 | |
| Almatica Pharma LLC | $372.15 | 2021-2024 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.78 | 2021-2025 | Jardiance |
| Pfizer INC. | $329.69 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.11 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $204.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $143.91 | 2021-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.66 | 2022-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $97.18 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $90.74 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $88.58 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $87.60 | 2021-2025 | Reyvow, Emgality, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $78.83 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $57.56 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $57.30 | 2023-2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $43.48 | 2022 | |
| Mylan Specialty L.P. | $42.41 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $34.32 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $32.54 | 2024-2025 | Gvoke Hypopen |
| Lundbeck LLC | $20.60 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $15.94 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $14.62 | 2023 | Ajovy |
| Sanofi Pasteur INC. | $14.06 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $13.07 | 2021 | |
| Merck Sharp & Dohme LLC | $12.37 | 2021 | |
| Genentech USA, INC. | $7.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.